解剖学报 ›› 2019, Vol. 50 ›› Issue (5): 677-683.doi: 10.16098/j.issn.0529-1356.2019.05.023

• 综述 • 上一篇    下一篇

亚甲蓝治疗缺血性脑卒中的研究进展

张孟钦1 卢剑飞2 陈春花1*   

  1. 1. 北京大学医学部基础医学院人体解剖学与组织学胚胎学系,北京 100083; 2. 上海交通大学基础医学院解剖学与生理学系,上海 200025
  • 收稿日期:2018-10-23 修回日期:2018-11-22 出版日期:2019-10-06 发布日期:2019-12-10
  • 通讯作者: 陈春花 E-mail:cch@bjmu.edu.cn
  • 基金资助:
    Kappa 阿片受体在缺血性脑卒中中的作用及机制研究

Progress in the therapeutic use of methylene blue in ischemic stroke

ZHANG Meng-qin1 LU Jian-fei2 CHEN Chun-hua 1*   

  1. 1. Department of Human Anatomy and HistoEmbryology, School of Basic Medical Sciences, Peking University Health Science Center,Beijing 100083, China; 2. Department of Anatomy and Physiology, Shanghai Jiao Tong University College of Basic Medical Sciences,Shanghai 200025, China
  • Received:2018-10-23 Revised:2018-11-22 Online:2019-10-06 Published:2019-12-10
  • Contact: CHEN Chun-hua E-mail:cch@bjmu.edu.cn

摘要:

脑卒中作为全球高致死、高致残的疾病,一直被广泛研究。亚甲蓝作为一种被美国食品药品管理局(FDA)批准用于治疗高铁血红蛋白血症和氰化物中毒的药物已有一百二十余年,而在近期研究中发现其具有神经保护作用,并在缺血性脑卒中的动物模型中展现出良好的保护作用。我们就近年来亚甲蓝治疗缺血性脑卒中的研究进行简要综述。

关键词:  亚甲蓝, 缺血性脑卒中, 神经保护

Abstract:

Stroke has been widely studied as a highly lethal and highly disabling disease worldwide. Methylene blue approved by the Food and Drug Administration(FDA) of the United States has been used in the treatment of methemoglobinemia and cyanide poisoning for more than one hundred and twenty years. In recent studies, it has been found to have neuroprotective effects and is effective in a few of animal models of ischemic stroke. This article briefly reviews the recent research on the therapeutic use of methylene blue in ischemic stroke.

Key words: Methylene blue, Ischemic stroke, Neuroprotection